

# Familiarity of Symptom Dimensions in Depression

Ania Korszun, PhD, MD, MRCPsych; Valentina Moskvina, PhD; Shyama Brewster, BSc Joint (Hons); Nick Craddock, MB, PhD, MRCPsych; François Ferrero, MD; Michael Gill, MD, MRCPsych, FTCD; Ian Richard Jones, MB, PhD, MRCPsych; Lisa Anne Jones, BSc (Hons), PhD; Wolfgang Maier, MD; Ole Mors, MD, PhD; Michael J. Owen, PhD, FRCPSych; Martin Preisig, MD, MPH; Theodore Reich, MD; Marcella Rietschel, MD; Anne Farmer, MD, FRCPSych; Peter McGuffin, MB, PhD, FRCP, FRCPSych

**Background:** Depression is a clinically heterogeneous disorder thought to result from multiple genes interacting with environmental and developmental components. A dimensional rather than a categorical approach to depressive phenotype definition may be more useful for identification of susceptibility genes.

**Objectives:** To perform an exploratory factor analysis on a range of depressive and anxiety symptoms in a large, well-defined sample of depressed siblings, as well as a confirmatory factor analysis in a separate large group of unrelated depressed subjects, and to analyze correlations of identified symptom dimensions between depressed siblings.

**Design:** Subjects (N = 1034), including 475 sibling pairs, with a history of at least 2 depressive episodes were recruited from the Depression Network Study, a large-scale multicenter collection of families affected by recurrent unipolar depression. Subjects were interviewed using the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) and diagnosed according to the DSM-IV and the *International Classification of Diseases, 10th Revision*, using a computerized scoring program (CATEGO5). Fac-

tor analysis was carried out on 26 depression symptom items, including 4 anxiety screening items. Confirmatory factor analysis was performed on an independent sample of 485 depressed individuals.

**Results:** Four interpretable factors were identified: (1) mood symptoms and psychomotor retardation; (2) anxiety; (3) psychomotor agitation, guilt, and suicidality; and (4) appetite gain and hypersomnia. For each symptom group, a quantitative scale was constructed, and correlations between siblings were calculated. There was a moderate degree of sibling homotypia for some depressive symptoms, and factors 1, 2, and 3 showed significant positive familial correlation (0.145 [ $P = .001$ ], 0.335 [ $P < .001$ ], and 0.362 [ $P < .001$ ], respectively).

**Conclusions:** This is the first study of large, well-defined samples of depressed subjects in whom symptom dimensions have been derived and then confirmed using independent material. The significant correlations between siblings for 3 of the dimensions suggest substantial familial, perhaps genetic, etiologies.

*Arch Gen Psychiatry.* 2004;61:468-474

**F**OR THE LAST 30 YEARS, DEPRESSION has been conceptualized mainly as a single syndrome that represents the final common pathway of a range of etiological factors. Both current classification systems of psychiatric disorders reflect this view (*DSM-IV* and *International Classification of Diseases, 10th Revision [ICD-10]*). However, depression comprises disparate symptoms, with disturbances of mood, thinking, sleep, appetite, and motor activity that do not all occur in the same distribution in every depressed individual. There is also considerable clinical overlap between symptoms of depression and anxiety. A unified biological explanation of depression has not been established, and this has led to questions about the validity of present classification systems and to conjectures about biologically distinct subcategories of depression.<sup>1</sup>

Depression is a clinically heterogeneous disorder thought to result from the interaction of genetic and environmental fac-

tors.<sup>2-4</sup> However, before susceptibility genes can be identified, it is crucial to achieve an optimal definition of depressive phenotypes. Broadly speaking, 2 approaches have been used for this: a categorical one in which individuals are fitted into subcategories that are separate and mutually exclusive, or a dimensional one in which symptoms are grouped together within different symptom complexes or "symptom dimensions" that can coexist to different degrees in individual patients. In this study, we explore using a dimensional approach to delineate the genetic architecture of depression.

Factor analysis is a useful tool for discovering structures in multivariate data and allows the major groupings, or dimensions, of correlated symptoms to be identified by looking at the highest factor loading for each symptom. Exploratory factor analysis starts from the raw data without any preconceptions, yielding suggested factors that are consistent with the data but must be justified by a plausible

Author affiliations are listed at the end of this article.

interpretation. Confirmatory factor analysis, on the other hand, is used to confirm or reject an assumed factor structure by testing it against independent data.

In the past, the construct of depression has been subjected to various factor analytic studies exploring different concepts of subtypes of depression, ranging from a 2-factor model of neurotic vs endogenous depression<sup>5-7</sup> to a 10-factor model,<sup>8</sup> with more recent focus on the atypical depressive subtype.<sup>9</sup> This approach has renewed potential in light of current understanding of a genetic contribution to the etiology of depression. For instance, a particular symptom dimension might represent the action of a contributory gene or group of genes, and a particular combination of such genes may result in a characteristic phenotype. Identification of symptom dimensions could thus lead to definition of a more appropriate classification system for depression, particularly for genetic studies.

Subsequent demonstration that symptom dimensions identified in this way are correlated in pairs of affected relatives would provide external validation of the proposed factor structure and suggest usefulness for genetic studies. This type of approach has been used to explore the classification and heritability of schizophrenia,<sup>10,11</sup> but there have been fewer studies of the familiarity of symptom dimensions in unipolar depression. Although previous work has shown familiarity between categorical subtypes of major depression,<sup>12,13</sup> to our knowledge, there has not been a large systematic study of sibling correlations of depressive dimensions derived by factor analysis.

The aims of this study were therefore (1) to identify depressive symptom dimensions by performing an exploratory factor analysis on a range of depressive and anxiety symptoms in a large, well-defined sample of depressed siblings diagnosed using accepted standardized criteria; (2) to perform a confirmatory factor analysis in a separate large group of unrelated depressed subjects assessed using the same clinical research methods to validate the results of the exploratory factor analysis; and (3) to provide further validation of the identified symptom dimensions by analyzing their correlations between depressed siblings.

## METHODS

### SUBJECTS

The main part of the analysis was carried out on subjects recruited for a large international multicenter genetic study of siblings with depression (depression network study [DeNT]) conducted at the following 8 clinical centers: St Louis, MO, London, England, Cardiff, Wales, Birmingham, England, Dublin, Ireland, Lausanne, Switzerland, Aarhus, Denmark, and Bonn, Germany. Confirmatory factor analysis was carried out on subjects recruited from a multicenter case-control depression study (depression case-control study [DeCC]) conducted in Birmingham, Cardiff, and London. Ethical approval was first obtained from the appropriate local ethics committees in each of the countries involved, and every participant gave written informed consent.

Both studies used similar methods for subject ascertainment. Subjects were identified from psychiatric clinics, hospitals, and general medical practices and from volunteers responding to media advertisements. White subjects older than 18 years were included if they had experienced 2 or more episodes of unipolar depression of at least moderate severity, separated by at least 2 months of remission, as defined by *DSM-IV* and *ICD-10*. In the

DeNT study, subjects were included if they had at least 1 full sibling older than 18 years meeting the same inclusion criteria. Subjects were excluded if either sibling was adopted or if they were the monozygotic twin of any other sibling in the study.

Exclusion criteria for the DeCC and DeNT included a history of psychotic symptoms that were mood incongruent or present when there was no evidence of a mood disturbance, intravenous drug use with a lifetime diagnosis of dependency, depression occurring solely in relation to alcohol or substance abuse, or depression secondary to medical illness or medication. Subjects were also excluded from both studies if there was a clear diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, or transient psychotic disorders in first- or second-degree relatives.

## CLINICAL ASSESSMENT

All subjects were interviewed using the Schedules for Clinical Assessment in Neuropsychiatry (SCAN),<sup>14</sup> a set of instruments validated in assessing, measuring, and classifying the symptoms of major adult psychiatric disorders. Subjects identified their 2 worst episodes of depression, and SCAN items were rated from the worst and second worst episodes. Most items are coded on an ordinal scale indicating the presence and severity of items (general rating of anxiety, general rating of phobias, sleep problem with depressed mood, and morning depression, 0-1; hypersomnia and appetite gain, 0-2; suicide or self-harm, 0-4; and the remainder of items, 0-3). The ratings from the SCAN interviews were entered into a computerized scoring program, CATEGO5, which provides diagnoses according to *DSM-IV* and *ICD-10* operational definitions.

## AGREEMENT BETWEEN RATERS ACROSS SITES

All interviewers from each site undertaking the DeNT study attended a 4-day SCAN training course in the United Kingdom. Additional interrater reliability meetings were held regularly at each site, and annually the interviewers from all sites took part in a joint interrater reliability exercise, with a mean  $\kappa$  across centers of 0.77 (range, 0.63-0.89), giving a substantial level of interrater agreement.<sup>15</sup> Raters from the 3 United Kingdom sites undertaking the DeCC study also participated in a 4-day SCAN training program and regular local interrater reliability meetings. In addition, intersite joint audiotape rating sessions were undertaken via telephone conferencing.

## DATA ANALYSIS


### Correlation of Symptoms Between Episodes

Spearman rank correlation coefficients were calculated for depressive symptoms between worst and second worst episodes.

### Correlation of Symptoms Between Siblings

To remove the effects of sex and age on the depressive symptoms, each symptom was adjusted by age and sex in the DeCC and DeNT samples. The SAS PROC MIXED (SAS Institute, Cary, NC) procedure was used to fit a linear model with age as a covariate and sex as a fixed effect. The residuals were considered as continuous variables and used for further analysis. Data were also analyzed with symptoms adjusted for the age at first onset of depression; however, as no significant effect of age at onset was found, all results are presented based on age and sex adjustment only.

Intraclass correlations were calculated for adjusted depressive symptoms between affected sibling pairs. Intraclass correlations were derived as  $(MSb - MSw) / (MSb + [k - 1]MSw)$ , where  $MSb$  and  $MSw$  are mean squares between and within siblings, respectively, obtained using analysis of variance for the



The linear model used in the confirmatory factor analysis. Four-factor model with cross-loadings and factor and error covariances. Unbroken lines connect symptom boxes with factors and errors. Dashed lines indicate cross-loadings; curved lines, factor covariances; and e1 through e26, error covariances (for clarity, the error covariances are not plotted).

random-effects model,<sup>11</sup> and  $k$  is the number of subjects in the class ( $k=2$  for sib pairs). In families with more than 2 members, each sibling pair contributed 1 independent pair, each trio (proband, sibling 1, and sibling 2) contributed 2 independent pairs (proband-sibling 1 and proband-sibling 2), each quartet contributed 3 independent pairs, and so on.

#### EXPLORATORY FACTOR ANALYSIS

Factor analysis was performed on 26 adjusted depression symptom items from the SCAN interview questions, representing a broad range of depressive symptoms, and 4 screening questions for the presence of anxiety disorders, using SAS PROC FACTOR. To assess the effect of latent dependencies between sib pairs stemming from the same family, we adjusted each symptom for the family (random) effect in addition to the sex and age adjustment. The SAS PROC MIXED procedure was used to fit a mixed model with age as a covariate, sex as a fixed effect, and family effect as a random effect. The residuals were used for the factor analysis. Initial factors were extracted using the principal components method, and rotations were then performed by the PROMAX method. To simplify interpretation, different rotations are used: orthogonal rotation is used if the assumption is that factors are uncorrelated, and oblique (including PROMAX) rotation is used if the factors are correlated with each other, as in the present analysis. The number of meaningful factors was determined by the scree plot.

#### CONFIRMATORY FACTOR ANALYSIS

Confirmatory maximum likelihood factor analysis, using structural equation modeling, was performed to test the factor construction obtained from the DeNT data against the DeCC data (Figure). The PROC CALIS in SAS was used to carry out the confirmatory factor analysis. Several goodness-of-fit measures were used to assess different versions of the construction: the goodness-of-fit index (GFI) and the GFI adjusted for degrees of freedom,<sup>16</sup> comparative fit index,<sup>17</sup> nonnormed fit index,<sup>18</sup> and root-mean-square error of approximation.<sup>19</sup> To prove that a model fits the

data, the accepted standard requirements for the goodness-of-fit indices are as follows: GFI, GFI adjusted for degrees of freedom, and comparative fit index greater than 0.95; nonnormed fit index greater than 0.9; and root-mean-square error of approximation less than 0.05.<sup>20-23</sup>

#### FAMILIALITY OF SYMPTOM DIMENSIONS

A quantitative scale was constructed for each of the symptom dimensions identified. All sex- and age-adjusted symptom items were used to construct quantitative scales, and subjects were scored by calculating the weighted mean of items present for each symptom dimension, with corresponding factor loadings as weight. To identify the significance of the familial effect, intra-class correlations were calculated.

## RESULTS

#### DEPRESSION NETWORK STUDY

Individuals ( $N = 1034$ ) were recruited from all 8 sites, and all individuals were included in the factor analyses. In some cases, families had to be excluded (eg, because of noncompliance or insufficient severity of depression in the sibling). Analysis was conducted on 403 families and 156 single subjects, with 403 probands and 475 siblings yielding 486 sib pairs. The sex distribution was 31% men and 69% women. The overall age range at assessment was 18 to 80 years; the mean  $\pm$  SD age was  $45 \pm 12$  years. The mean  $\pm$  SD age at onset of the first episode of depression was  $24 \pm 12$  years (range, 3-74 years). The mean  $\pm$  SD period between assessment and the worst episode of depression was  $9.1 \pm 9.8$  years. **Table 1** shows the characteristics of the sample obtained from each site.

**Table 1. Sex and Age of Subjects Recruited at Each Site**

Site	Male-Female	Age, Mean (SD), y
	Ratio	
Aarhus, Denmark (n = 39)	17:22	41 (9)
Birmingham, England (n = 123)	40:83	48 (13)
Bonn, Germany (n = 149)	36:113	49 (13)
Cardiff, Wales (n = 123)	39:84	44 (10)
Dublin, Ireland (n = 175)	49:126	40 (11)
Lausanne, Switzerland (n = 155)	48:107	45 (12)
London, England (n = 154)	51:103	45 (10)
St Louis, Mo (n = 116)	41:75	46 (11)
<b>Total (N = 1034)</b>	<b>321:713</b>	<b>45 (12)</b>

### DEPRESSION CASE-CONTROL STUDY

Four hundred eighty-five depressed individuals (31.9% men and 68.1% women) were recruited from the 3 United Kingdom sites. The age range at assessment was 18 to 82 years (mean  $\pm$  SD age, 47  $\pm$  12 years). Both studies were designed for genetic analysis. Therefore, to simplify later linkage and association analyses, subjects were restricted to those with white parents and grandparents. The frequency and severity of clinically significant depressive symptoms (as defined by SCAN) in all subjects are shown in **Table 2**. The severity was calculated as the ratio of the mean score to the maximum score for each symptom.

### DATA ANALYSIS

#### Correlations of Symptoms Between Episodes

Spearman rank correlation coefficients for all symptoms between episodes in the DeNT sample were highly significant ( $P < .001$ ). Therefore, further analyses were carried out on symptoms reported during the worst episodes.

#### Correlations of Symptoms Between Siblings

For the between-siblings correlation analysis, the data consisted of 346 pairs, 46 trios, 8 quartets, 2 quintets, and 1 sextet. The number of independent pairs from sibling pairs, trios, quartets, quintets, and sextets was therefore 346, 92, 24, 8, and 5, respectively. **Table 3** shows the correlation coefficients for depressive symptoms, corrected for age and sex effect, between siblings. Restlessness (0.307), anxiety symptoms (0.260-0.306), loss of libido (0.295), and irritability (0.258) showed the highest correlations.

### EXPLORATORY FACTOR ANALYSIS

To ensure that artifactual groupings did not result from the selection of several SCAN items that address similar symptoms (eg, initial insomnia and middle sleep period insomnia, problems with thinking, and problems with concentration), only one item was used for each type of symptom. Psychotic symptoms (delusions of guilt or worthlessness, delusions of catastrophe, hypochondriacal delusions in the context of depression, and auditory

**Table 2. Frequency and Severity of Symptoms in Depression Network Study (DeNT) and Depression Case-Control Study (DeCC) Samples**

Symptom	DeNT		DeCC	
	Frequency, %	Severity	Frequency, %	Severity
Depressed mood	98.84	0.93	98.97	0.94
Loss of reactivity	96.81	0.84	99.38	0.93
Anhedonia	96.62	0.89	99.59	0.91
Loss of interest	95.84	0.85	95.05	0.82
Loss of energy or drive	95.16	0.85	95.26	0.87
Hopelessness	91.01	0.82	93.40	0.86
Loss of self-esteem	88.39	0.78	88.04	0.79
Subjectively inefficient thinking	88.01	0.74	90.31	0.80
Fatigability and exhaustion	70.31	0.62	59.79	0.51
Suicidality	62.09	0.25	64.95	0.25
Subjective feeling of retardation	61.70	0.49	61.44	0.50
Irritability	58.99	0.40	53.61	0.35
General rating of anxiety	57.54	0.58	55.26	0.55
Loss of appetite	57.45	0.50	68.45	0.61
Pathological guilt	56.96	0.44	65.57	0.49
Subjectively described restlessness	52.51	0.42	42.89	0.34
Morning depression	50.77	0.51	45.98	0.46
Early waking	50.58	0.39	52.37	0.39
Loss of weight	50.58	0.23	54.02	0.24
Loss of libido	47.10	0.39	42.89	0.36
Preoccupation with death or catastrophe	42.75	0.34	36.49	0.17
Free-floating anxiety	38.30	0.29	49.69	0.38
Hypersomnia	32.21	0.26	27.84	0.22
General rating of phobias	29.21	0.29	35.05	0.35
Guilty ideas of reference	26.20	0.20	29.48	0.22
Anxious foreboding with autonomic symptoms	23.21	0.16	31.55	0.24
Gain of weight	20.50	0.15	18.56	0.13
Gain of appetite	13.64	0.13	9.90	0.09
Delusions of guilt or worthlessness	2.22	0.01	1.44	0.01
Hypochondriacal delusions	1.64	0.01	1.24	0.01
Auditory hallucinations	1.23	0.01	2.89	0.01
Delusions of catastrophe	0.77	0.01	0.82	0.01

hallucinations with affective state) were excluded from the analysis because they occurred in too few subjects.

All 1034 subjects were used for the exploratory factor analysis. The scree plot indicated 4 substantive factors, which accounted for 39% of the variance. The 4 symptom dimensions are shown in **Table 4** and comprised the following symptom groupings. Factor 1 comprises the mood symptoms, including depressed mood, anhedonia, loss of hope, loss of reactivity, loss of interest, and low self-esteem. It also includes psychomotor retardation symptoms, with inefficient thinking and loss of energy and libido. Factor 2 comprises the anxiety dimension, including general rating of anxiety, free-floating anxiety, anxious foreboding with autonomic symptoms, and general rating of phobias. Factor 3 comprises psychomotor agitation with restlessness and irritability, pathological guilt and guilty ideas of reference, suicidality, and morning worsening of depressed mood.

**Table 3. Intraclass Correlations (ICC) of Depressive Symptoms Adjusted for Age and Sex Between Siblings**

Symptom	ICC (95% Confidence Interval)	P Value
Subjectively described restlessness	0.307 (0.222 to 0.388)	<.001
Free-floating anxiety	0.306 (0.222 to 0.307)	<.001
Loss of libido	0.295 (0.204 to 0.380)	<.001
General rating of anxiety	0.260 (0.173 to 0.343)	<.001
Irritability	0.258 (0.171 to 0.341)	<.001
Fatigability and exhaustion	0.233 (0.145 to 0.318)	<.99
Anxious foreboding with autonomic symptoms	0.226 (0.138 to 0.311)	>.99
Suicidality	0.176 (0.087 to 0.262)	>.99
General rating of phobias	0.168 (0.079 to 0.255)	>.99
Subjective feeling of retardation	0.165 (0.074 to 0.253)	>.99
Anhedonia	0.155 (0.066 to 0.243)	>.99
Morning depression	0.142 (0.051 to 0.230)	.001
Loss of interest	0.128 (0.038 to 0.216)	.003
Hopelessness	0.117 (0.026 to 0.206)	.003
Guilty ideas of reference	0.116 (0.025 to 0.206)	.007
Loss of appetite	0.110 (0.015 to 0.203)	.01
Depressed mood	0.107 (0.017 to 0.195)	.01
Loss of self-esteem	0.105 (0.014 to 0.194)	.01
Early waking	0.101 (0.008 to 0.192)	.12
Preoccupation with death or catastrophe	0.081 (-0.011 to 0.171)	.04
Hypersomnia	0.075 (-0.161 to 0.166)	.053
Loss of energy or drive	0.065 (-0.025 to 0.154)	.08
Loss of reactivity	0.05 (-0.026 to 0.155)	.08
Subjectively inefficient thinking	0.050 (-0.042 to 0.141)	.14
Pathological guilt	0.006 (-0.085 to 0.097)	.45
Gain of appetite	-0.002 (-0.097 to 0.093)	.52

Factor 4 includes appetite gain and hypersomnia negatively correlated with appetite loss and early waking.

There was cross-loading of suicidality between factors 1 and 3 and cross-loading of hypersomnia between factors 1 and 4.

#### CONFIRMATORY FACTOR ANALYSIS

Subjects from the DeCC sample (n=485) were used in the confirmatory factor analysis of the hypothesized factor structure derived from the exploratory factor analysis of the DeNT data set. The best fit (GFI, 0.99; GFI adjusted for *df*, 0.9; comparative fit index, 0.99; nonnormed fit index, 0.87; and root-mean-square error of approximation, 0.036) was obtained for the 4-factor model, which included cross-loadings, correlations between factors, and error covariances. The improvement in model fit after including the error covariances suggests that some of the errors are correlated and indicates that the data may also contain a nonlinear finer structure. Nevertheless, the linear modeling yields acceptable fit results and provides a good approximation.

#### FAMILIALITY OF SYMPTOM DIMENSIONS

Intraclass correlations between sibs were calculated for the 4 factors. Factor 1 showed a low but significant correlation of 0.145 ( $P=.001$ ). Factors 2 and 3 showed highly significant moderate correlations of 0.335 ( $P<.001$ ) and

**Table 4. Rotated Factor Pattern (PROMAX Rotation Method)\***

Symptom Dimension	Factor 1	Factor 2	Factor 3	Factor 4
Depressed mood	0.63			
Anhedonia	0.70			
Hopelessness	0.51			
Loss of reactivity	0.54			
Loss of interest	0.73			
Subjectively inefficient thinking	0.56			
Subjective feeling of retardation	0.45			
Loss of energy or drive	0.66			
Loss of libido	0.35		-0.34	
Loss of self-esteem	0.47			
General rating of anxiety		0.79		
Free-floating anxiety		0.77		
Anxious foreboding with autonomic symptoms		0.72		
General rating of phobias		0.59		
Subjectively described restlessness			0.67	
Irritability			0.64	
Fatigability and exhaustion			0.46	
Pathological guilt			0.51	
Guilty ideas of reference			0.46	
Suicidality	0.26		0.27	
Preoccupation with death or catastrophe			0.27	
Morning depression			0.22	
Loss of appetite				0.7
Early waking				0.45
Gain of appetite				-0.81
Hypersomnia	0.34			-0.21

\*Values less than 0.25 are not shown unless they are the largest.

0.362 ( $P<.001$ ), respectively. The correlation between siblings for factor 4 was 0.075 ( $P=.052$ ).

#### COMMENT

Both samples were from genetic studies designed to ascertain individuals with moderate to severe recurrent depression. This is reflected by the type and frequency of symptoms occurring in this study group, with a 62% frequency of suicidality and a high frequency of depressive cognitions and disturbances in thinking. Depressed mood, loss of mood reactivity, and anhedonia were almost ubiquitous symptoms, which would be expected as these are core requirements for a diagnosis of depression. However, there was only a small proportion of subjects with psychotic symptoms, reflecting not only the fact that psychotic depression is rare<sup>24</sup> but also the method of recruitment. Subjects were recruited from outpatient rather than inpatient settings, and many volunteered in response to media advertisements. Consequently, they represent a moderately ill group, rather than the more severe type of illness more commonly associated with psychotic symptoms.

There was a high correlation of symptoms between the worst and second worst episodes within individuals; therefore, further analysis was carried out on symptoms occurring in the worst episodes. Kendler and colleagues<sup>25</sup> have shown that, although there are limitations to using retrospectively acquired data, depression that is sufficiently severe or disabling as to require treatment tends to be more memorable and therefore more reli-

ably reported. Furthermore, it has been demonstrated that ratings from a past episode of depression are comparable to contemporary accounts derived from case notes.<sup>26</sup> On the other hand, memories of symptoms that occurred during a severe episode of depression may confound memory of other episodes, resulting in recall of the same features for all episodes.<sup>27</sup> Therefore, in the present study, the use of data from only the worst episodes produced a more robust analysis.

Reliability was further increased by inclusion of only those individuals who had experienced 2 or more depressive episodes. In this sample, there was a slightly greater preponderance of women (2.2:1) than is usually found in community samples, in which a 1.7 times greater depression risk for women has been reported.<sup>28</sup> This probably also reflects recruitment methods and the fact that women are more likely to volunteer to participate in research studies. The higher mean age of 45 years in this study reflects the fact that only subjects with recurrent depression were included. Overall, the samples used in the present study were representative of moderate to severe nonpsychotic depression.

After eliminating the possible effects of age, age at onset of depression, and sex, factor analysis of a range of SCAN items identified 4 interpretable factors. The first factor (18% of the variance) comprised depressed mood symptoms that are almost ubiquitous among individuals with depression, as well as symptoms associated with psychomotor retardation and loss of libido and self-esteem. The second factor, consisting of the 4 anxiety symptoms, formed an independent dimension of depression accounting for 9% of the variance. There is considerable overlap between depressive and anxiety symptoms, and anxiety as a symptom<sup>29</sup> is the norm rather than the exception in major depression; 58% of individuals with a lifetime episode of major depression also meet criteria for an anxiety disorder.<sup>30</sup> In this study, the frequency of anxiety symptoms ranged from 23% (anxious foreboding) to 58% (general rating of anxiety). Interestingly, there was no cross-loading between the anxiety factor and any other dimension.

The third factor identifies a strong grouping of signs of agitation, such as irritability and restlessness, with suicidality and other depressive cognitions, in particular, guilt. Morning worsening of depressed mood is also part of this dimension. The association of suicidality and agitation is interesting; although ideally psychomotor agitation needs to be documented by an observer, irritability and subjective restlessness are indicators of its presence. Parker<sup>1</sup> has proposed a hierarchical model of depression in which there are separate neurobiological processes generating differing clinical features. He further postulates that psychomotor disturbance is a distinct component associated with "melancholic" and more severe depression. Suicidality is an indicator of more severe depression, at least in the sense that it increases the risk of mortality from depression, and recognition of this suicidality-agitation dimension has important clinical implications if the presence of agitation predicts suicide.

The fourth factor comprised increased appetite and hypersomnia negatively correlated with early awakening and appetite loss. There has been recent interest in

the atypical depressive subtype (ie, hypersomnia with increased weight and appetite),<sup>31</sup> and a study<sup>13</sup> of subtypes of depression in twins found appetite and weight to be among the most discriminating symptoms and findings and identified an atypical depressive subgroup. In our analysis, we focused on appetite changes rather than weight changes, as the former is a more reliable measure and not as dependent on the length of a depressive episode. The strong separation of increased appetite and sleep into a separate dimension adds some support to the existence of a separate atypical dimension.

Three of the 4 symptom dimensions showed a significant correlation between siblings, adding validation of this factor structure. Factor 1 showed a low level of correlation, but as this largely comprises a group of symptoms that are obligatory for a diagnosis of depression and thus almost ubiquitous in this sample and in any sample defined under our present classification systems, this dimension may be more indicative of severity rather than representing a particular phenotypic component, and, whereas heritability contributes to the latter, severity is not familial.

Factors 2 (anxiety) and 3 (psychomotor agitation, guilt, and suicidality) showed a highly significant moderate degree of correlation (0.335 and 0.362, respectively) between siblings. There was also significant correlation between siblings of several individual symptoms (Table 2), but with lower correlations overall than for symptom dimensions, suggesting that dimensions could be more robust phenotypic markers. However, although our findings support the existence of an atypical symptom dimension, it does not appear to have a familial etiology. This dimension and the individual symptoms of hypersomnia and appetite gain show low sibling correlation.

The correlations between siblings for symptom dimensions reported herein are much higher than those found in similar factor analyses of schizophrenia<sup>10,13</sup> and are more likely to reflect genetic or environmental factors shared between the depressed siblings, rather than modifying factors. Genetic effects are the most important contributor to familial aggregation,<sup>3</sup> and if the factor structure shown in this study represents different components of genetic liability, then such factors could be used in genetic studies to identify more homogeneous subsamples of depression.

Limitations of this study are that subjects were ascertained in different ways at the various sites, relying on advertisement in some centers, and in others being mainly recruited from psychiatric clinics; therefore, findings cannot necessarily be generalized to other studies. This study was carried out on white subjects only; therefore, results cannot be extrapolated to other ethnic groups. Furthermore, there are potential sources of bias in that volunteering may be more likely in sibling pairs who have more similar types of depressive symptoms, and that subjects came from families with more than 1 sib with depression. However, the confirmatory analysis demonstrated similar findings in an independent group of single depressed subjects (DeCC). A further limitation, as already discussed, is that we made cross-sectional assessments of psychiatric symptoms; although a longitudinal

or repeated assessment would have been preferable, assessments were retrospective and therefore subject to memory bias.

There has been a long-standing and largely unresolved debate as to whether depression is best classified as a collection of syndromes or as a single entity in which cases differ mainly in terms of severity.<sup>32</sup> In this study of large, well-defined samples of depressed subjects, symptom dimensions have been derived and then confirmed using independent material. We also found highly significant correlations between siblings. Caution is required when interpreting correlation between siblings, but recent twin studies<sup>3,33</sup> suggest that shared environmental effects in depression are small or nonexistent. We can therefore conclude that the dimensions corresponding to factors 1, 2, and 3 have substantial familial, perhaps genetic, etiologies. Although this is not the same as finding 2 causally distinct syndromes, the identification of depressive symptom dimensions provides the potential for a more refined phenotypic definition for molecular genetic studies of depression using a quantitative trait locus approach. Furthermore, such dimensions may prove useful in psychopharmacological research, in which it has been pointed out that the development of new drugs to treat depression would be facilitated by dissecting the current "monolithic" definition of the disorder into component symptom complexes.<sup>34</sup>

Submitted for publication June 2, 2003; final revision received January 13, 2004; accepted January 20, 2004.

From the Department of Psychological Medicine, University of Wales College of Medicine, Cardiff (Dr Korszun, Moskvina, Craddock, and Owen), GlaxoSmithKline Medical Genetics, Middlesex (Ms Brewster), Department of Psychiatry, University of Birmingham, Birmingham (Drs I. R. Jones and L. A. Jones), and Medical Research Council Social Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College, London (Drs Farmer and McGuffin), England; Department of Psychiatry, University of Geneva, Geneva (Dr Ferrero), and Departement Universitaire de Psychiatrie Adult, Prilly-Lausanne (Dr Preisig), Switzerland; Department of Psychiatry, Trinity Centre for Health Sciences, St James' Hospital, Dublin, Ireland (Dr Gill); Department of Psychiatry, University of Bonn, Bonn (Dr Maier), and Division of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Mannheim (Dr Rietschel), Germany; Department of Psychiatric Demography, Psychiatric Hospital in Aarhus, Aarhus, Denmark (Dr Mors); and Department of Psychiatry, Washington University School of Medicine, St Louis, Mo (Dr Reich).

The DeNT study is funded by grants from GlaxoSmithKline Clinical Genetics and the DeCC study by the Medical Research Council, United Kingdom.

We acknowledge the following individuals: Sian Caesar; Carly Cooper, BSc; Miriam Craddock, BSc; Fiona Cule, MA; Subodh Dave, MRCPsych; Laura Dean, BSc; Caroline Drain, MHS; Emma Dunn, BSc; Magda Gross, BSc; Andrea Hough, BSc; Izabella Jurewicz, MRCPsych; Svetlana Kovalenko, MD; Louisa Lyon, BSc; Liz McGillivray, BSc; Vicky Swainson, MSc; and Debra Woolway.

Corresponding author and reprints: Ania Korszun, PhD, MD, MRCPsych, Department of Psychological Medicine, Uni-

versity of Wales College of Medicine, Heath Park, Cardiff CF14 4XN, United Kingdom (e-mail: akorszun@umich.edu).

## REFERENCES

1. Parker G. Classifying depression. *Am J Psychiatry*. 2000;157:1195-1203.
2. Kendler KS. Major depression and the environment: a psychiatric genetic perspective. *Pharmacopsychiatry*. 1998;31:5-9.
3. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. *Am J Psychiatry*. 2000;157:1552-1562.
4. McGuffin P, Owen MJ, Gottesman II, eds. *Psychiatric Genetics and Genomics*. Oxford, England: Oxford University Press; 2002.
5. Kendell RE. The classification of depressive illness. *Br J Psychiatry*. 1970;117:347-348.
6. Rassaby E, Paykel ES. Factor patterns in depression. *J Affect Disord*. 1979;1:187-194.
7. MacFadyen HW. The classification of depressive disorders, I: a review of statistically based classification studies. *J Clin Psychol*. 1975;31:380-394.
8. Gullion CM, Rush AJ. Toward a generalizable model of symptoms in major depressive disorder. *Biol Psychiatry*. 1998;44:959-972.
9. Sullivan PF, Kessler RC, Kendler KS. Latent class analysis of lifetime depressive symptoms in the National Comorbidity Survey. *Am J Psychiatry*. 1998;155:1398-1406.
10. Cardno AG, Jones LA, Murphy KC, Sanders RD, Asherson P, Owen MJ, McGuffin P. Dimensions of psychosis in affected sibling pairs. *Schizophr Bull*. 1999;25:841-850.
11. Wickham H, Walsh C, Asherson P, Taylor C, Sigmundson T, Gill M, Owen MJ, McGuffin P, Murray R, Sham P. Familiality of symptom dimensions in schizophrenia. *Schizophr Res*. 2001;47:223-232.
12. Leckman JF, Weissman MM, Prusoff BA, Caruso KA, Merikangas KR, Pauls DL, Kidd KK. Subtypes of depression. *Arch Gen Psychiatry*. 1984;41:833-838.
13. Sullivan PF, Prescott CA, Kendler KS. The subtypes of major depression in a twin registry. *J Affect Disord*. 2002;68:273-284.
14. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R, Jablenski A, Regier D, Sartorius N. SCAN: Schedules for Clinical Assessment in Neuropsychiatry. *Arch Gen Psychiatry*. 1990;47:589-593.
15. Everitt BS. *Making Sense of Statistics in Psychology*. Oxford, England: Oxford University Press; 1996:291.
16. Joreskog KG, Sorbom D. *LISREL VI: Analysis of Linear Structural Relationships by Maximum Likelihood, Instrumental Variables, and Least Squares Methods*. 4th ed. Uppsala, Sweden: Dept of Statistics, University of Uppsala; 1986.
17. Bentler PM. Comparative fit indexes in structural models. *Psychol Bull*. 1990;107:238-246.
18. Bentler PM, Bonett DG. Significance tests and goodness of fit in the analysis of covariance structures. *Psychol Bull*. 1980;88:588-606.
19. Steiger JH. Structural model evaluation and modification: an interval estimation approach. *Multivariate Behav Res*. 1990;25:173-180.
20. Marsh HW, Balla JW, Hau K-T. An evaluation of incremental fit indices: a clarification of mathematical and empirical properties. In: Marcoulides GA, Schumacker RE, eds. *Advanced Structural Equation Modeling Issues and Techniques*. Mahwah, NJ: Lawrence Erlbaum Associates Inc; 1996:315-354.
21. Browne MW, Cudeck R. Alternative ways of assessing model fit. In: Bollen KA, Long JS, eds. *Testing Structural Equation Models*. Newbury Park, Calif: Sage Publications; 1993:136-161.
22. Byrne BM. *Structural Equation Modeling With LISREL, PRELIS, and SIMPLIS: Basic Concepts, Applications, and Programming*. Mahwah, NJ: Lawrence Erlbaum Associates Inc; 1998.
23. Bollen KA, Long JS. *Testing Structural Equation Models*. Newbury Park, Calif: Sage Publications; 1993.
24. Johnson J, Horwath E, Weissman MM. The validity of major depression with psychotic features based on a community study. *Arch Gen Psychiatry*. 1991;48:1075-1081.
25. Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ. The lifetime history of major depression in women. *Arch Gen Psychiatry*. 1993;50:863-870.
26. McGuffin P, Katz R, Aldrich J. Past and present state examination: the assessment of "lifetime ever" psychopathology. *Psychol Med*. 1986;16:461-465.
27. Rice JP, Rochberg N, Endicott J, Lavori PW, Miller C. Stability of psychiatric diagnoses. *Arch Gen Psychiatry*. 1992;49:824-830.
28. Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the National Comorbidity Survey, I: lifetime prevalence, chronicity and recurrence. *J Affect Disord*. 1993;29:85-96.
29. Ninan PT, Berger J. Symptomatic and syndromal anxiety and depression. *Depress Anxiety*. 2001;14:79-85.
30. Kessler RC, Nelson CB, McGonagle KA, Liu J, Swartz M, Blazer DG. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. *Br J Psychiatry Suppl*. June 1996:17-30.
31. Posternak MA, Zimmerman M. Partial validation of the atypical features subtype of major depressive disorder. *Arch Gen Psychiatry*. 2002;59:70-76.
32. Farmer A, McGuffin P. The classification of the depressions: contemporary confusion revisited. *Br J Psychiatry*. 1989;155:437-443.
33. McGuffin P, Katz R, Watkins S, Rutherford J. A hospital-based twin register of the heritability of DSM-IV unipolar depression. *Arch Gen Psychiatry*. 1996;53:129-136.
34. Hyman SE, Fenton WS. Medicine: what are the right targets for psychopharmacology? *Science*. 2003;299:350-351.

- DSM-III-R (SCID), I: history, rationale, and description. *Arch Gen Psychiatry*. 1992; 49:624-629.
30. Dwivedi Y, Pandey GN. Administration of dexamethasone upregulates protein kinase C activity and the expression of  $\gamma$  and  $\epsilon$  protein kinase C isozymes in the rat brain. *J Neurochem*. 1999;72:380-387.
  31. Dwivedi Y, Pandey GN. Quantitation of 5HT<sub>2A</sub> receptor mRNA in human post-mortem brain using competitive RT-PCR. *Neuroreport*. 1998;9:3761-3765.
  32. Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. *Biol Psychiatry*. 2000;48:740-754.
  33. Young LT, Wang JF, Woods CM, Robb JC. Platelet protein kinase C  $\alpha$  levels in drug-free and lithium-treated subjects with bipolar disorder. *Neuropsychobiology*. 1999;40:63-66.
  34. Coull MA, Lowther S, Katona CLE, Horton RW. Altered brain protein kinase C in depression: a postmortem study. *Eur Neuropsychopharmacol*. 2000;10:283-288.
  35. Dean B, Opeskin K, Pavey G, Hill C, Keks N. Changes in protein kinase C and adenylate cyclase in the temporal lobe from subjects with schizophrenia. *J Neural Transm*. 1997;104:1371-1381.
  36. Manji HK, Lenox RH. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic depressive illness. *Biol Psychiatry*. 1999;46:1328-1351.
  37. Lopez JF, Palkovits M, Arato M, Mansour A, Akil H, Watson SJ. Localization and quantification of pro-opiomelanocortin mRNA and glucocorticoid receptor mRNA in pituitaries of suicide victims. *Neuroendocrinology*. 1992;56:491-501.
  38. Pandey GN, Dwivedi Y. Effects of adrenal glucocorticoids on protein kinase C (PKC) binding sites, PKC activity and expression of PKC isozymes in the rat brain. *J Neurochem*. 2000;74:S21D.
  39. Banks GC, Li Y, Reeves R. Differential in vivo modifications of the HMGI(Y) monohistone chromatin proteins modulate nucleosome and DNA interactions. *Biochemistry*. 2000;39:8333-8346.
  40. Hocevar BA, Burns DJ, Fields AP. Identification of protein kinase C (PKC) phosphorylation sites on human lamin B: potential role of PKC in nuclear lamina structural dynamics. *J Biol Chem*. 1993;268:7545-7552.
  41. Frey MR, Clark JA, Leontieva O, Uronis JM, Black AR, Back JD. Protein kinase C signaling mediates a program of cell cycle withdrawal in the intestinal epithelium. *J Cell Biol*. 2000;151:763-778.
  42. Vertegaal AC, Kuiperij HB, Yamaoka S, Courtois G, van der Eb M, Zanema A. Protein kinase C- $\alpha$  is an upstream activator of the I $\kappa$ B kinase complex in the TPA signal transduction pathway to NF- $\kappa$ B in U2OS cells. *Cell Signal*. 2000;12:759-768.
  43. Yuan LW, Gambee JE. Phosphorylation of p300 at serine 89 by protein kinase C. *J Biol Chem*. 2000;275:40946-40951.
  44. Nakashima S. Protein kinase C $\alpha$  (PKC $\alpha$ ): regulation and biological function. *J Biochem (Tokyo)*. 2002;132:669-675.
  45. Leitges M, Schmedt C, Guinamard R, Davoust J, Schaal S, Stabel S, Tarakhovskiy A. Immunodeficiency in protein kinase C $\beta$ -deficient mice. *Science*. 1996; 273:768-791.
  46. Saito N, Kikkawa U, Nishizuka Y, Tanaka C. Distribution of protein kinase C-like immunoreactive neurons in rat brain. *J Neurosci*. 1988;8:369-382.
  47. Saito N, Shirai Y. Protein kinase C $\gamma$  (PKC $\gamma$ ): function of neuron specific isotype. *J Biochem (Tokyo)*. 2002;132:683-687.
  48. Kano M, Hashimoto K, Chen C, Abeliovich A, Aiba A, Kurihara H, Watanabe M, Inoue Y, Tonegawa S. Impaired synapse elimination during cerebellar development in PKC $\gamma$  mutant mice. *Cell*. 1995;83:1223-1231.
  49. Campbell JM, Payne AP, Gilmore DP, Russel D, McGadey J, Clarke DJ, Branton R, Davies RW, Sutcliffe RG. Age change in dopamine levels in the corpus striatum of Albino Swiss (AS) and AS/AGU mutant mice. *Neurosci Lett*. 1997;239: 54-56.
  50. Payne AP, Campbell JM, Russel D, Favor G, Sutcliffe RG, Bennet NK, Davies RW, Stone TW. The AS/AGU rat: a spontaneous model of disruption of degeneration in the nigrostriatal dopaminergic system. *J Anat*. 2000;196:629-633.

### Correction

**Errors in Table.** In the Original Article by Korszun et al titled "Familiality of Symptom Dimensions in Depression," published in the May issue of the ARCHIVES (2004;61:468-474), errors occurred in Table 3 on page 472. In that table, the P values for fatigability and exhaustion, anxious foreboding with autonomic symptoms, suicidality, general rating of phobias, subjective feeling of retardation, and anhedonia should have been listed as <.001.